{
    "id": 13387,
    "fullName": "ABL1 Q252H",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 Q252H lies within the protein kinase domain of the Abl1 protein (UniProt.org). Q252H results in a loss of inhibitor binding and has also been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL1 (PMID: 16046538, PMID: 21562040), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 5631,
                    "pubMedId": 16046538,
                    "title": "Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16046538"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "Q252H",
    "createDate": "10/29/2015",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119213,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862969G>T",
        "cDna": "c.756G>T",
        "protein": "p.Q252H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6260,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 100% (2/2) of chronic myeloid leukemia patients harboring ABL1 Q252H in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 Q252H were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16837,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 Q252H in the context of BCR-ABL1 was identified in chronic myeloid leukemia patients who relapsed on Gleevec (imatinib) treatment (PMID: 12204532).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14949,
                    "pubMedId": 12204532,
                    "title": "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12204532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13573,
            "profileName": "ABL1 Q252H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22968,
            "profileName": "BCR - ABL1 ABL1 Q252H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119213,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862969G>T",
            "cDna": "c.756G>T",
            "protein": "p.Q252H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}